Clinical Trial

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

Study acronym: GLIA-MAC
Completed
View on ClinicalTrials.gov →
Summary
The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up
Trial Details
NCT Number NCT07526857
Lead Sponsor Federico II University
Conditions Diabetic Retinopathy, DR
Enrollment 60 participants
Start Date 2025-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13